Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Revolution Medicines (RVMD) Leases (2020 - 2025)

Revolution Medicines (RVMD) has 6 years of Leases data on record, last reported at $132.1 million in Q4 2025.

  • For Q4 2025, Leases rose 12.38% year-over-year to $132.1 million; the TTM value through Dec 2025 reached $132.1 million, up 12.38%, while the annual FY2025 figure was $132.1 million, 12.38% up from the prior year.
  • Leases reached $132.1 million in Q4 2025 per RVMD's latest filing, down from $134.4 million in the prior quarter.
  • Across five years, Leases topped out at $134.4 million in Q3 2025 and bottomed at $25.0 million in Q1 2023.
  • Average Leases over 5 years is $70.7 million, with a median of $59.1 million recorded in 2021.
  • Peak YoY movement for Leases: surged 215.25% in 2021, then tumbled 57.32% in 2023.
  • A 5-year view of Leases shows it stood at $59.7 million in 2021, then fell by 7.73% to $55.1 million in 2022, then skyrocketed by 40.07% to $77.1 million in 2023, then soared by 52.35% to $117.5 million in 2024, then grew by 12.38% to $132.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $132.1 million in Q4 2025, $134.4 million in Q3 2025, and $114.0 million in Q2 2025.